ExoCoBIO Co., Ltd.

Founded in 2017 and headquartered in Seoul, South Korea, ExoCoBIO Co. , Ltd. operates in the regenerative medicine sector, focusing on exosome technologies. The company has raised a total of KRW 11,000 mn through multiple funding rounds, with the latest being a Series C round on July 4, 2023.

The funding was led by investors such as DT&Investment and Focus Asset Management. Yong Yi is the founder, while Byong-seung Cho serves as CEO. ExoCoBIO specializes in exosome-based regenerative therapeutics and bio-pharmaceuticals, primarily utilizing its proprietary ExoSCRT™ technology. This innovation enables the production of high-purity, high-efficacy exosomes for a range of applications including aesthetic treatments and immuno-oncology.

Their product lineup includes advanced skincare solutions like ASCE+ Skin and ASCE+ Hair, along with specialized formulations such as Exomage and Celosome, targeting dermatologists and healthcare providers in Asia, North America, and Europe. In 2024, ExoCoBIO generated revenue amounting to KRW 38,052,744. 1 and achieved an EBITDA of KRW 19,996,838. 3, reflecting its successful sales model focused on direct sales and partnerships within the aesthetic and medical fields.

ExoCoBIO plans to launch new advanced products designed to expand its portfolio of exosome-based solutions. The company is targeting market expansion into North America and Europe by the end of 2024, leveraging recent funding from the Series C round to support these initiatives. This funding round involved K2 Investment Partners acquiring a 40% minority stake in July 2023, indicating strong investor confidence in the company's growth trajectory.